Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Anavex Life Sciences (AVXL)
NASDAQ:AVXL
AVXL Stock Chart & Stats
Day’s Range― - ―
52-Week Range$3.25 - $14.44
Previous CloseN/A
Volume1.46M
Average Volume (3M)2.28M
Market Cap
$889.71M
Enterprise Value$349.45M
Total Cash (Recent Filing)N/A
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)―
Beta1.89
Next Earnings
Feb 06, 2025EPS Estimate
-0.15Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.51
Shares Outstanding84,815,510
10 Day Avg. Volume1,763,787
30 Day Avg. Volume2,281,260
Standard Deviation0.25
R-Squared0.02
Alpha0.04
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-33.40
P/FCF Ratio0.00
Enterprise Value/Market Cap0.39
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda-16.74
Forecast
1Y Price Target
$42.00Price Target Upside353.07% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
---
Bulls Say, Bears Say
Bulls Say
Clinical EfficacyBlarcamesine demonstrated clinically meaningful improvement over 48 weeks, with the primary endpoint ADAS-Cog13 score improvement being greater than two points.
Intellectual PropertyNew patent claims issued, protecting novel polymorph of blarcamesine until at least July 2039.
Market OpportunitiesThe European market opportunity for blarcamesine could be highly lucrative, with an estimated 7 million people in Europe with Alzheimer's disease.
Bears Say
Clinical Data ChallengesNegative clinical data with blarcamesine could impact its prospects in Alzheimer's disease, Parkinson's disease dementia, and Rett syndrome.
Financial RisksRisks include possible long-term dilution risk.
Regulatory RisksRisks include negative clinical data with blarcamesine in Alzheimer's disease, Parkinson's disease dementia, and Rett syndrome, as well as failure to obtain approval for its target indications.
---
Ownership Overview
3.05% Insiders
8.57% Mutual Funds
0.23% Other Institutional Investors
75.66% Public Companies and Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
AVXL FAQ
What was Anavex Life Sciences’s price range in the past 12 months?
Anavex Life Sciences lowest stock price was $3.25 and its highest was $14.44 in the past 12 months.
What is Anavex Life Sciences’s market cap?
Anavex Life Sciences’s market cap is $889.71M.
When is Anavex Life Sciences’s upcoming earnings report date?
Anavex Life Sciences’s upcoming earnings report date is Feb 06, 2025 which is in 2 days.
How were Anavex Life Sciences’s earnings last quarter?
Anavex Life Sciences released its earnings results on Dec 23, 2024. The company reported -$0.14 earnings per share for the quarter, beating the consensus estimate of -$0.163 by $0.023.
Is Anavex Life Sciences overvalued?
According to Wall Street analysts Anavex Life Sciences’s price is currently Undervalued.
Does Anavex Life Sciences pay dividends?
Anavex Life Sciences does not currently pay dividends.
What is Anavex Life Sciences’s EPS estimate?
Anavex Life Sciences’s EPS estimate is -0.15.
How many shares outstanding does Anavex Life Sciences have?
Anavex Life Sciences has 84,815,510 shares outstanding.
What happened to Anavex Life Sciences’s price movement after its last earnings report?
Anavex Life Sciences reported an EPS of -$0.14 in its last earnings report, beating expectations of -$0.163. Following the earnings report the stock price went up 29.548%.
Which hedge fund is a major shareholder of Anavex Life Sciences?
Among the largest hedge funds holding Anavex Life Sciences’s share is Deerfield Management Company, LP. It holds Anavex Life Sciences’s shares valued at 599K.
---
Anavex Life Sciences Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$42.00 (353.07% Upside)
$42.00 (353.07% Upside)
Blogger Sentiment
Bullish
AVXL Sentiment 90%
Sector Average 71%
Sector Average 71%
Hedge Fund Trend
Increased
By 8.3K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▲ 0.2%
Last 30 Days ▲ 15.8%
Last 30 Days ▲ 15.8%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
59.42%
12-Months-Change
Fundamentals
Return on Equity
-35.76%
Trailing 12-Months
Asset Growth
-12.19%
Trailing 12-Months
Company Description
Anavex Life Sciences
Anavex Life Sciences (AVXL) is a clinical-stage biopharmaceutical company dedicated to the development of novel drug candidates for the treatment of central nervous system (CNS) diseases. The company's primary focus is on leveraging its proprietary SIGMACEPTOR platform to develop therapies aimed at addressing neurodegenerative and neurodevelopmental disorders. Anavex's leading product candidates target conditions such as Alzheimer's disease, Parkinson's disease, and Rett syndrome, with a mission to improve the quality of life for patients suffering from these debilitating conditions.
---
AVXL Earnings Call
Q4 2024
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call reflected a generally positive outlook with significant advancements in Alzheimer's treatment development and strong financial positioning. However, the company reported a net loss for the quarter.Read More>---
AVXL Stock 12 Month Forecast
Average Price Target
$42.00
▲(353.07% Upside)
Technical Analysis
ACADIA Pharmaceuticals
―
Biogen
―
Cassava Sciences
―
Axsome Therapeutics
―
Adial Pharmaceuticals
―
Best Analysts Covering AVXL
1 Year
1 Year Success Rate
16/27 ratings generated profit
1 Year Average Return
+89.83%
initiated a buy rating 7 months ago
Copying Jason Kolbert's trades and holding each position for 1 Year would result in 59.26% of your transactions generating a profit, with an average return of +89.83% per trade.
---